Syntara (SNT) investor relations material

Industry context and investment rationale

• Recent failures in single-asset healthcare companies highlight the risk, while diversified pipelines offer more opportunities for returns.

• Syntara presents a model with multiple late-stage assets, all expected to deliver results within 12 months.

• Institutional investors hold 43% of shares, indicating strong confidence and rare support for a company of this size.

• The company is well covered by four banks and has a cash runway through early 2027.

Pipeline overview and clinical progress

• Lead drug amsulostat targets myelofibrosis, with positive phase II results and further studies in myelodysplastic syndrome (MDS) and pancreatic cancer.

• All ongoing studies are funded by non-dilutive sources, minimizing shareholder dilution.

• Additional programs include skin scarring (two studies) and a Parkinson’s-related sleep disorder, both with data expected in the next 6–12 months.

Myelofibrosis and commercial landscape

• Myelofibrosis is a fatal bone marrow cancer with limited treatment options; current JAK inhibitors have significant side effects.

• Amsulostat demonstrated strong efficacy in symptom reduction and spleen volume, with a favorable safety profile and no serious adverse events.

• The market for JAK inhibitors is nearly AUD 2 billion annually, with recent M&A deals in the space exceeding AUD 1.7 billion.

• FDA discussions are ongoing, with a pivotal study protocol decision and potential partnering expected in Q2.